The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

The double-blind, placebo-controlled study included 298 patients (pNET cohort: n=99; epNET cohort: n=199) who were randomly assigned 2:1 to ... in Carcinoid and Neuroendocrine Tumors at Dana ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

Omitting endocrine therapy in ER-low breast cancer was associated with a 23% relative increase in the risk of death in 3 ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World Health Organization standards, the abnormal activation of oncogene FOXR2 ...

Understanding these interactions is important for the development of new therapies for cancer treatment. We identify an age-related subpopulation of RETNLγ + LCN2 + senescence-like neutrophils ...

and neuroendocrine tumors (NETs), which are neoplasms that arise from cells of the endocrine and nervous systems.